Absence of clinical benefit of FDG PET-CT in staging T1 part-solid lung adenocarcinoma

Clin Radiol. 2022 Mar;77(3):195-202. doi: 10.1016/j.crad.2021.11.013. Epub 2021 Dec 23.


Aim: To assess the rates of nodal and metastatic disease and change in management when staging part-solid T1 lung adenocarcinomas using integrated 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography (PET)-computed tomography (CT) in a UK population.

Materials and methods: This was a retrospective review of PET-CT examinations performed to stage radiologically suspected T1 part-solid lung adenocarcinoma (n=58) from two different centres. Rates of detection of nodal and metastatic disease, change in management, and final patient outcome were recorded.

Results: PET-CT changed the stage in one patient from N0 to N1. It did not change final management in any patient.

Conclusions: In this UK population, PET-CT had minimal additional diagnostic benefit in staging patients with T1 part-solid lung adenocarcinoma. Especially given its cost, the inclusion of PET-CT for this indication in guidelines should be reviewed.

Publication types

  • Multicenter Study

MeSH terms

  • Adenocarcinoma of Lung / diagnostic imaging*
  • Adenocarcinoma of Lung / pathology
  • Aged
  • Aged, 80 and over
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Lung Neoplasms / diagnostic imaging*
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Positron Emission Tomography Computed Tomography / economics
  • Positron Emission Tomography Computed Tomography / methods*
  • Radiopharmaceuticals*
  • Retrospective Studies
  • United Kingdom


  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18